News & Investors

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Cara Therapeutics Enters Into Development and Commercial Alliance with Maruishi for Novel Kappa Opioid Agonist, CR845, in Japan
Focus on Acute Pain and Uremic Pruritus
View HTML
Toggle Summary "Preclinical Profile of CR845" View HTML
Toggle Summary Cara Banks $15M for Pursuit of Nonaddictive Pain Drug, by Donna Young (BioWorld Today)
Cara Banks $15M for Pursuit of Nonaddictive Pain Drug, by Donna Young (BioWorld Today) The $15 million Series D financing Cara Therapeutics Inc. closed this week will go a long way toward advancing the development of its peripherally restricted kappa opioid agonist CR845, said CEO Derek Chalmers...
View HTML
Toggle Summary Cara Receives Breakthrough Therapy Designation from FDA for I.V. CR845 for the Treatment of Chronic Kidney Disease-Associated Pruritus in Hemodialysis Patients
Phase 3 safety extension trial underway
View HTML
Toggle Summary Cara Therapeutics Achieves Milestone Payments From Japan and South Korea Partners for Development of CR845 in Uremic Pruritus
$2.5M Milestones Earned for Advancement of CR845 in Phase 2 Clinical Trials in U.S. and Japan SHELTON, Conn. , Oct. 13, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain
View HTML
Toggle Summary Cara Therapeutics and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) Enter into Ex-U.S. Licensing Agreement to Commercialize KORSUVA™ Injection in Dialysis Patients with Pruritus
Cara receives upfront payment of $50 million in cash and an equity investment of $20 million Cara eligible for up to $470 million in regulatory and commercial milestones VFMCRP to commercialize KORSUVA injection worldwide except in the U.S., Japan and South Korea Cara to commercialize KORSUVA
View HTML
Toggle Summary Cara Therapeutics Announces Addition to the NASDAQ Biotechnology Index
SHELTON, Conn. , Dec. 18, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to selectively target peripheral kappa opioid receptors, today announced that it has been selected for addition
View HTML
Toggle Summary Cara Therapeutics Announces Appointment of Joseph Stauffer, D.O., as Chief Medical Officer
SHELTON, Conn. , Dec. 2, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced the
View HTML
Toggle Summary Cara Therapeutics Announces Appointment of Robert Medve, M.D., as Chief Medical Officer
Experienced Pain Drug Developer and Expert in Human Abuse Liability to Lead Clinical Development of CR845 for the Treatment of Acute and Chronic Pain
View HTML
Toggle Summary Cara Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Over-Allotment Option
SHELTON, Conn., Feb. 5, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, today announced the closing of its initial
View HTML